targeting difficult-to-treat solid tumors

iOncologi announced the issuance of a foundational U.S. patent covering RNA-based formulations that enhance tumor responsiveness to immune checkpoint inhibitors. The patent, exclusively licensed from the University of Florida Research Foundation, underpins iOncologi’s UNIFYRs™ (UNiversal Immune FortifYing RNAs) platform — a new class of RNA therapeutics designed to reprogram both systemic and intratumoral immunity to overcome resistance across solid tumors.

Findings recently published in Nature Biomedical Engineering and Nature validate the scientific basis of this approach, linking RNA-driven immune activation to improved survival among cancer patients receiving  immune checkpoint inhibitor therapy. This milestone strengthens iOncologi’s leadership in RNA immunotherapy and accelerates the advancement of its next-generation therapeutic pipeline.

PRESS RELEASE

PRESS RELEASE

NBC NEWS COVERAGE

iOncologi has partnered with SandboxAQ, an Alphabet spinout and leader in AI & quantum technology, to co-develop a next-generation immunotherapy for glioblastoma (GBM)—one of the most lethal and treatment-resistant brain tumors.

The collaboration combines iOncologi’s clinical-stage immunotherapy platforms with SandboxAQ’s AQBioSim™ AI engine to rapidly design, simulate, and optimize precision therapies. This partnership brings together deep tech and translational medicine to tackle GBM—a cancer with a median survival of less than 15 months and limited treatment options.

Together, we aim to bring an AI-built, immune-guided, and patient-adaptable immunotherapy into the clinic within 18 months—redefining the future of solid tumor immunotherapy.

Press Release

FOX Business News Interview